News & Blog

2023 FARA Fellows

Larimar Therapeutics Receives FDA Clearance

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich’s Ataxia Trial and to Initiate Open Label Extension Trial

Lexeo Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy

FARA Celebrates the 15th Annual Ataxian Athlete Initiative (AAI) for People with Ataxia

May 2023 – Advocacy Newsletters

PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort – First Quarter 2023 Financial Results

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohor

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results

April 2023 – Advocacy Newsletter

First Medication to Treat Friedreich’s Ataxia Approved on Rare Disease Day!